Agent | Mechanism | Stage of Clinical Development | References |
---|---|---|---|
Safingol | SPHK1 inhibitor | Demonstrated safety in combination with cisplatin in Phase I trial in solid tumours | [43, 46, 47] |
Fingolimod | S1P receptor antagonist | Licenced for use in multiple sclerosis. No data on clinical use in cancer | [29, 30, 44] |
(FTY720) | |||
Sonepcizumab | Humanised S1P neutralising monoclonal antibody | Demonstrated safety in Phase I trial in solid tumours | [48, 49] |
(LT1009) |